Actelion vs. Torrent: Consent Judgment in Macitentan Patent Dispute
Was möchten Sie als Nächstes tun?
Wählen Sie Ihren Weg entsprechend Ihren aktuellen Bedürfnissen:
📋 Fallzusammenfassung
| Fallbezeichnung | Actelion Pharmaceuticals Ltd. v. Torrent Pharmaceuticals Ltd. |
| Fallnummer | 1:24-cv-03990 (D.N.J.) |
| Gericht | US-Bezirksgericht für den Bezirk New Jersey |
| Dauer | March 19, 2024 – April 18, 2024 30 days |
| Ergebnis | Plaintiff Win — Consent Judgment with Injunction & Validity Admission |
| Streitige Patente | |
| Beschuldigte Produkte | Torrent’s generic macitentan 10 mg oral tablets (ANDA No. 211107) |
Fallübersicht
Die Parteien
⚖️ Kläger
Swiss-headquartered biopharmaceutical company, a subsidiary of Johnson & Johnson, known for its leadership in pulmonary arterial hypertension (PAH) therapies.
🛡️ Beklagter
Global generic pharmaceutical manufacturer based in India, whose U.S. subsidiary filed ANDA No. 211107 for generic macitentan.
Streitige Patente
This landmark case involved two key patents covering the blockbuster PAH drug OPSUMIT® (macitentan), which protect both the active pharmaceutical ingredient and its formulation or methods of use. These patents are registered with the U.S. Patent and Trademark Office (USPTO).
- • US7094781B2 — Covers pharmaceutical compositions and methods relating to macitentan.
- • US10946015B2 — Covers formulation or use claims related to the OPSUMIT® product.
Entwickeln Sie ein Generikum?
Ensure your product does not infringe existing pharmaceutical patents before regulatory submission.
Das Urteil und die rechtliche Analyse
Ergebnis
The case resolved via **Consent Judgment** in a remarkably swift 30-day period. Torrent Pharmaceuticals expressly **admitted the validity and enforceability** of U.S. Patent No. 7,094,781 and conceded that its proposed generic macitentan product would infringe prior to patent expiration. A **permanent injunction** was entered against Torrent, prohibiting any infringing activity related to ANDA No. 211107.
Wichtige rechtliche Fragen
This resolution reinforces the potency of the Hatch-Waxman Act, particularly **35 U.S.C. § 271(e)(2)**, which defines the filing of an ANDA for a patented drug as an act of infringement. Torrent’s explicit admission of validity and infringement stands out, as many ANDA litigations result in settlements without such a definitive concession. This binding judicial admission forecloses future challenges related to this ANDA, providing Actelion with robust and expedited protection for its macitentan patent estate in the District of New Jersey, a key venue for pharmaceutical IP disputes.
Freedom-to-Operate-Analyse (FTO)
This case highlights critical IP risks in pharmaceutical patent litigation. Choose your next step:
📋 Die Auswirkungen dieses Falls verstehen
Informieren Sie sich über die spezifischen Risiken und Auswirkungen dieses Rechtsstreits.
- Alle 2 verwandten Patente in diesem Technologiebereich anzeigen
- See which companies are most active in PAH IP
- Understand claim scope and validity patterns
🔍 Risiko meines Generikums überprüfen
Run a comprehensive FTO analysis for your own active pharmaceutical ingredient (API) or formulation.
- Input your API description or technical features
- KI identifiziert potenziell blockierende Formulierungs-/Verfahrenspatente
- Get actionable regulatory pathway risk assessment
Hochrisikogebiet
Composition of matter patents for macitentan
2 wichtige Patente
Covering macitentan API & formulation
Komplexe Design-Umgehung
Formulation and method of use claims
✅ Wichtigste Erkenntnisse
Consent judgments with explicit validity admissions provide stronger protection than settlements silent on patent merit.
Verwandte Rechtsprechung suchen →The District of New Jersey remains the preferred venue for Hatch-Waxman litigation due to judicial familiarity and favorable procedural environment.
Präzedenzfälle erkunden →A 30-day resolution timeline is achievable in ANDA cases when leverage is clear and both parties are commercially motivated to resolve early.
Analysieren Sie Trends bei Rechtsstreitigkeiten →Injunction scope should expressly cover affiliates, successors, and assigns to prevent corporate restructuring workarounds.
Review injunction examples →Häufig gestellte Fragen
The primary patent was U.S. Patent No. 7,094,781 (US7094781B2), designated the “Licensed Patent” in the consent judgment. U.S. Patent No. 10,946,015 (US10946015B2) was also identified among the patents involved in the litigation.
Torrent admitted that US7094781’s claims are valid, enforceable, and would be infringed by commercial activities related to ANDA No. 211107 covering generic macitentan 10 mg tablets. The parties resolved for undisclosed consideration, and a permanent injunction was entered.
It establishes a binding judicial record of US7094781’s validity in the context of ANDA No. 211107, and signals to other potential ANDA challengers that Actelion will enforce its patent estate aggressively and with speed.
Sind Sie bereit, Ihre Patentstrategie zu stärken?
Schließen Sie sich den über 18.000 Fachleuten aus dem Bereich des geistigen Eigentums an, die PatSnap Eureka nutzen, um mit KI-gestützter Präzision Recherchen zum Stand der Technik durchzuführen, Patentanmeldungen zu erstellen und Wettbewerbslandschaften zu analysieren.
Referenzen
- USPTO Patent Full-Text Database — US7094781B2
- PACER Case Lookup — 1:24-cv-03990
- FDA ANDA Database
- U.S. Patent and Trademark Office — Patent Search
- PatSnap – Lösungen für den Umgang mit geistigem Eigentum für Anwaltskanzleien
Dieser Artikel dient ausschließlich zu Informationszwecken und stellt keine Rechtsberatung dar. Alle Angaben zu den Fällen stammen aus öffentlich zugänglichen Gerichtsakten. Informationen zu den Funktionen der Plattform finden Sie auf PatSnap.